

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY
COMMITTEE
Recommendations Summary
August 6, 2008**

Public Testimony

Name	Company	Drug	Class
Hoa Pham	Amgen	Enbrel	Cytokine - CAM
Pam Sardo	Abbott	Humira	Cytokine - CAM
Kurt Celke	WI Rheum Assoc	Cytokine – CAM	Cytokine – CAM
Bryan Yaeger	Roche	Boniva	Bone Resorption
Lisa Goetz	Procter & Gamble	Actonel	Bone Resorption
Ted Hough	Amylin	Byetta & Symlin	Hypoglycemics Incretin Mimetics
Robert Calder	Merck	Januvia/Janumet/ Singulair	Hypoglycemics Incretin Mimetics
Kristin Hanson	Novo Nordisk	Insulin	Insulins
Shelley Carroll	BMS	Baraclude	Hepatitis B
Krishna Patel/Helen Ha	Schering Plough	Noxafil, Avelox	Antifungals, oral
Steve Whiten	Taro		Antifungals, topical
Robert Moreland	Astellas	Atopic Dermatitis	Atopic Dermatitis
Dona Wininsky	Amer. Lung Assoc.	Anticholinergics	Anticholinergics
Neal Jain	WI Asthma Coalition	Anticholinergics	Anticholinergics
Ileen Gilbert	Medical College of WI	Spiriva	Anticholinergics
Donald Bukstein	Dean Clinic	Beta Agonists	Beta Agonists
Kristi Klett	GSK	Veramyst	Intranasal Rhintis
Todd Mahr	Gunderson Lutheran	Leukotriene Modifier	Leukotriene Modifier
Thomas Castillo	Physician	Xalatan	Ophthalmics Glaucoma
Dr. Luellwitz	Allergan	Combigan	Glaucoma
Jim Katz	Alcon	Vigamox	Ophthalmics Quinolones
Art Shedden	Vistakon	Iquix	Ophthalmics Quinolones
Stan Rane	Novartis	Exelon Patch	Alzheimers Agents
Ann Marie Williams	Wyeth	Pristiq	Other
Michael J. Eis	Forest	Lexapro	SSRIs
Erwin Montgomery	Boehringer Ingelheim	Mirapex	Antiparkinsons Agents
Jessica Hahn	American	Antiparkinsons Agents	Antiparkinsons

	Parkinson Disease Assn		Agents
John Verbanac	Ortho McNeil	Invega, Concerta	Atypical Antipsychotics
Frank Cistaro	Astra Zeneca	Seroquel, Seroquel XR	Atypical Antipsychotics
Jerry Halverson	WI Psychiatric Assoc	Atypical Antipsychotics	Atypical Antipsychotics
Madan Uprety	Cumberland Memorial Hospital	Atypical Antipsychotics	Atypical Antipsychotics
Mike Asmus	Pfizer	Geodon	Atypical Antipsychotics
Lagenia Bailey	Otsuka	Abilify	Atypical Antipsychotics
Gil Golden	Azur	FazaClo	Atypical Antipsychotics
Ellen Schoenberger	Eli Lilly	Strattera	Stimulants & Related Agents
Michael Feld	Shire	Vyvanse	Stimulants & Related Agents

PA Committee members present at the meeting:

Catherine Decker, PharmD	Pat Towers	Shel Gross	Dr. Brad Fedderly
Dr. Kevin Izard	Rosanne Barber	Dr. Ward Brown	Dr. James Boblin
Steve Maike, RPh	Dr. Mike Witkovsky	Dr. Thomas Hirsch	Dr. Anthony DeFranco

Jason Helgerson read the script to move the meeting to the closed session.

Since the next part of the meeting is to discuss manufacturer-specific supplemental rebate amounts which needs to be confidential because of the competitive nature of the rebate agreements, I would ask for a motion to go into closed session.

State open meeting law requires that we record how each committee member votes on the motion to go into closed session. Therefore, we will be taking a roll call vote.

All members were in favor of the motion.

Dr Hirsch left prior to voting.

ANALGESICS/ANESTHETICS, TOPICAL						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
VOLTAREN (TOPICAL)	0.0%	NR	Yes			
LIDODERM (TOPICAL)	96.8%	NR	Yes			
FLECTOR (TOPICAL)	3.2%	NR	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Dr. Boblin seconded it.
 - All members were in favor of the motion.

NSAIDS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
PIROXICAM (ORAL)	2.5%	ON	Yes-Generic			
IBUPROFEN RX (ORAL)	44.6%	ON	Yes-Generic			
KETOROLAC (ORAL)	1.5%	ON	Yes-Generic			
MELOXICAM (ORAL)	3.6%	ON	Yes-Generic			
NAPROXEN RX (ORAL)	19.0%	ON	Yes-Generic			
DICLOFENAC (ORAL)	7.5%	ON	Yes-Generic			
FLURBIPROFEN (ORAL)	0.2%	ON	Yes-Generic			
KETOPROFEN (ORAL)	0.6%	ON	Yes-Generic			
OXAPROZIN (ORAL)	0.3%	OFF	No-Generic			
SULINDAC (ORAL)	0.6%	OFF	No-Generic			
ETODOLAC (ORAL)	1.7%	OFF	No-Generic			
INDOMETHACIN (ORAL/RECTAL)	2.6%	ON	Yes-Generic			
FENOPROFEN (ORAL)	0.0%	OFF	No-Generic			
NABUMETONE (ORAL)	5.6%	ON	Yes-Generic			
ARTHROTEC (ORAL)	0.5%	OFF	No			
PREVACID NAPRAPAC (ORAL)	0.0%	OFF	No			
CELEBREX (ORAL)	9.3%	ON	Yes			
TOLMETIN (ORAL)	0.0%	OFF	No-Generic			
MECLOFENAMATE (ORAL)	0.0%	ON	No-Generic			
MEFENAMIC ACID (ORAL)	0.0%	OFF	No-Generic			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Izard made the motion and Dr. Brown seconded it.
 - All members were in favor of the motion.

CYTOKINE AND CAM ANTAGONISTS

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
KINERET (INJECTION)	1.5%	ON	Yes			
RAPTIVA (INJECTION)	0.1%	ON	Yes			
ENBREL (INJECTION)	54.4%	ON	Yes			
HUMIRA (INJECTION)	44.0%	ON	Yes			

Dr. DeFranco arrived at the meeting at 2:54 p.m.

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Witkovsky made the motion and Ms. Barber seconded it.
 - All members were in favor of the motion.

ANDROGENIC AGENTS

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ANDRODERM (TRANSDERM.)	23.8%	ON	Yes			
ANDROGEL (TRANSDERM.)	66.2%	ON	Yes			
TESTIM (TRANSDERM.)	10.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Ms Towers seconded it
 - All members were in favor of the motion.

BONE RESORPTION SUPPRESSION AND RELATED AGENTS

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ACTONEL (ORAL)	6.3%	OFF	No	Yes	Yes	No
ALENDRONATE SODIUM (ORAL)	69.0%	ON	Yes-Generic			
FOSAMAX SOLUTION (ORAL)	0.3%	NR	Yes			
MIACALCIN (NASAL) (1OFMANY)	5.2%	ON	Yes			
EVISTA (ORAL)	4.8%	OFF	No			
FORTICAL (NASAL)	0.2%	OFF	No			
FOSAMAX PLUS D (ORAL)	10.4%	ON	Yes	No	Yes	
BONIVA (ORAL) (1OF3 BPROD)	3.7%	OFF	No			
DIDRONEL (ORAL)	0.0%	OFF	No			

- The Committee made a modification to the recommendations presented.

- Dr. Fedderly made the motion to modify the staff recommendations to add Actonel and remove Fosamax Plus D. This motion was seconded by Ms. Barber.
- There were 10 members in favor of the motion and Steve Maike was opposed. The motion passed.

PANCREATIC ENZYMES						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
DYGASE (ORAL)	0.2%	NR	Yes-Generic			
PANCRELIPASE (ORAL)	37.3%	NR	Yes-Generic			
LIPRAM (ORAL)	7.4%	NR	Yes			
VIOKASE (ORAL)	6.8%	NR	Yes			
PANCREASE MT (ORAL)	7.8%	NR	Yes			
LAPASE (ORAL)	0.6%	NR	Yes-Generic			
CREON (ORAL)	21.6%	NR	Yes			
ULTRASE (ORAL)	10.0%	NR	Yes			
PANCRECARB MS (ORAL)	8.4%	NR	No			

- The Committee made a motion to approve to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Ms. Towers seconded it.
 - All members were in favor of the motion.

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
JANUVIA (ORAL)	58.0%	ON	Yes			
JANUMET (ORAL)	5.7%	ON	Yes			
SYMLIN PENS (SUBCUTANE.)	0.8%	ON	Yes			
BYETTA PENS (SUBCUTANE.)	33.5%	ON	Yes			
SYMLIN (SUBCUTANE.)	2.1%	ON	Yes			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Ms. Towers seconded it.
 - All members were in favor of the motion.

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
HUMALOG (SUBCUTANE.)	15.5%	ON	Yes			
HUMULIN (SUBCUTANE.)	24.1%	ON	Yes			

HUMALOG MIX (SUBCUTANE.)	3.0%	ON	Yes			
NOVOLIN (SUBCUTANE.)	1.5%	OFF	No			
NOVOLIN PENS (SUBCUTANE.)	0.7%	OFF	No			
HUMALOG PENS (SUBCUTANE.)	6.0%	ON	Yes			
NOVOLOG (SUBCUTANE.)	3.5%	OFF	No			
NOVOLOG MIX 70/30 (SUBCUTANE.)	0.5%	OFF	No			
LANTUS (SUBCUTANE.)	29.4%	ON	Yes			
NOVOLOG MIX 70/30 PENS (SUBCUTANE.)	0.7%	OFF	No			
LEVEMIR (SUBCUTANE.)	1.5%	ON	Yes			
NOVOLOG PENS (SUBCUTANE.)	2.4%	OFF	No			
HUMULIN PENS (SUBCUTANE.)	1.6%	ON	Yes			
HUMALOG MIX PENS (SUBCUTANE.)	1.9%	ON	Yes			
LEVEMIR PENS (SUBCUTANE.)	1.6%	ON	Yes			
LANTUS PENS (SUBCUTANE.)	5.9%	ON	Yes			
APIDRA (SUBCUTANE.)	0.1%	OFF	No			
APIDRA PENS (SUBCUTANE.)	0.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Izard made the motion and Dr. Brown seconded it.
 - All members were in favor of the motion.

ANTIEMETICS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ONDANSETRON / ODT (ORAL)	92.6%	ON	Yes-Generic			
GRANISETRON (ORAL)	0.2%	ON	Yes-Generic			
MARINOL (ORAL)	3.6%	OFF	No			
EMEND (ORAL)	3.4%	ON	Yes			
CESAMET (ORAL)	0.0%	OFF	No			
ANZEMET (ORAL)	0.1%	OFF	No			
DRONABINOL	0.1%	OFF	No-Generic			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Dr. Witkovsky seconded it.
 - All members were in favor of the motion.

ANTIBIOTICS, VAGINAL

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
CLEOCIN (VAGINAL)	5.2%	NR	Yes			
CLINDAMYCIN (VAGINAL)	7.7%	NR	Yes-Generic			
CLINDESSE (VAGINAL)	23.0%	NR	Yes			
METRONIDAZOLE (VAGINAL)	64.1%	NR	Yes-Generic			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Dr. Witkovsky seconded it.
 - All members were in favor of the motion.

CEPHALOSPORINS AND RELATED ANTIBIOTICS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
CEPHALEXIN (ORAL)	24.8%	ON	Yes-Generic			
CEFACLOR (ORAL)	0.8%	ON	Yes-Generic			
CEFUROXIME (ORAL)	4.7%	ON	Yes-Generic			
AMOXICILLIN/CLAV TABLET (ORAL)	23.3%	ON	Yes-Generic			
CEFADROXIL (ORAL)	1.6%	ON	Yes-Generic			
AMOXICILLIN/CLAV SUSPENSION (ORAL)	22.4%	ON	Yes-Generic			
CEFPROZIL (ORAL)	5.2%	ON	Yes-Generic			
SUPRAX (ORAL)	0.3%	ON	Yes			
RANICLOR (ORAL)	0.0%	OFF	No			
CEDAX (ORAL)	0.0%	ON	No			
AUGMENTIN XR (ORAL)	0.2%	OFF	No			
CEFDINIR (ORAL)	16.0%	ON	Yes-Generic			
CEFPODOXIME (ORAL)	0.6%	ON	Yes-Generic			
SPECTRACEF (ORAL)	0.0%	ON	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Brown made the motion and Dr. Boblin seconded it.
 - All members were in favor of the motion.

FLUOROQUINOLONES, ORAL						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
CIPROFLOXACIN TABLETS (ORAL)	46.6%	ON	Yes-Generic			
NOROXIN (ORAL)	0.0%	OFF	No			
PROQUIN XR (ORAL)	0.0%	OFF	No			
LEVAQUIN (ORAL)	45.9%	ON	Yes			
AVELOX (ORAL)	6.8%	ON	Yes			
FACTIVE (ORAL)	0.0%	OFF	No			
CIPROFLOXACIN ER	0.0%	OFF	No-Generic			

(ORAL)						
OFLOXACIN (ORAL)	0.2%	ON	Yes-Generic			
CIPRO SUSPENSION (ORAL)	0.3%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Witkovsky made the motion and Mr. Maike seconded it.
 - All members were in favor of the motion. Dr. DeFranco was absent for the vote.

MACROLIDES/KETOLIDES						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ERYTHROMYCIN (ORAL)	1.3%	ON	Yes-Generic			
AZITHROMYCIN (ORAL)	94.7%	ON	Yes-Generic			
CLARITHROMYCIN (ORAL)	3.8%	ON	Yes-Generic			
ZMAX (ORAL)	0.0%	OFF	No			
KETEK (ORAL)	0.0%	OFF	No			
CLARITHROMYCIN ER (ORAL)	0.2%	OFF	No-Generic			

- The Committee made a motion to approve the recommendations as presented.
 - Ms. Towers made the motion and Mr. Gross seconded it.
 - All members were in favor of the motion. Dr. DeFranco was absent for the vote.

ANTIFUNGALS, ORAL						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
FLUCONAZOLE (ORAL)	61.0%	ON	Yes-Generic			
KETOCONAZOLE (ORAL)	1.7%	ON	Yes-Generic			
TERBINAFINE (ORAL)	2.9%	ON	Yes-Generic			
NYSTATIN (ORAL)	23.2%	ON	Yes-Generic			
CLOTRIMAZOLE (MUCOUS MEM)	2.1%	ON	Yes-Generic			
GRIS-PEG (ORAL)	1.3%	ON	Yes			
GRIFULVIN V TABLETS (ORAL)	0.5%	OFF	No			
GRISEOFULVIN SUSPENSION (ORAL)	6.4%	ON	Yes-Generic			
LAMISIL GRANULES (ORAL)	0.0%	NR	No			
ANCOBON (ORAL)	0.0%	OFF	No			
ITRACONAZOLE (ORAL)	0.5%	ON	Yes-Generic			
VFEND (ORAL)	0.4%	ON	Yes			
NOXAFIL (ORAL)	0.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Boblin made the motion and Dr. Fedderly seconded it.
 - All members were in favor of the motion.

ANTIFUNGALS, TOPICAL						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
NYSTATIN-TRIAMCINOLONE (TOPICAL)	8.6%	ON	Yes-Generic			
NYSTATIN (TOPICAL)	43.5%	ON	Yes-Generic			
CLOTRIMAZOLE-BETAMETHASONE (TOPICAL)	17.1%	ON	Yes-Generic			
CICLOPIROX SOLUTION (TOPICAL)	0.5%	ON	Yes-Generic			
ECONAZOLE (TOPICAL)	2.8%	ON	Yes-Generic			
KETOCONAZOLE (TOPICAL)	14.2%	ON	Yes-Generic			
NAFTIN (TOPICAL)	0.4%	OFF	No			
KETOCONAZOLE SHAMPOO (TOPICAL)	11.0%	ON	Yes-Generic			
XOLEGEL (TOPICAL)	0.0%	OFF	No			
CICLOPIROX CR/SUSP/GEL (TOPICAL)	0.8%	OFF	No-Generic			
VUSION (TOPICAL)	0.2%	OFF	No			
ERTACZO (TOPICAL)	0.0%	OFF	No			
LOPROX SHAMPOO (TOPICAL)	0.2%	OFF	No			
OXISTAT (TOPICAL)	0.6%	OFF	No			
MENTAX (TOPICAL)	0.0%	OFF	No			
CNL 8 (TOPICAL)	0.0%	NR	No			
EXTINA (TOPICAL)	0.0%	NR	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Decker made the motion and Dr. Brown seconded it.
 - All members were in favor of the motion.

ANTIPARASITICS, TOPICAL						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
EURAX (TOPICAL)	1.5%	NR	Yes			
PERMETHRIN (TOPICAL)	85.2%	NR	Yes-Generic			
OVIDE (TOPICAL)	9.2%	NR	Yes			
LINDANE (TOPICAL)	4.1%	NR	No-Generic			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Dr. Brown seconded it.

- All members were in favor of the motion.

ANTIVIRALS, ORAL						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ACYCLOVIR (ORAL)	13.3%	ON	Yes-Generic			
RIMANTADINE (ORAL)	0.2%	ON	Yes-Generic			
AMANTADINE (ORAL)	5.4%	ON	Yes-Generic			
RELENZA (INHALATION)	0.0%	ON	Yes			
TAMIFLU (ORAL)	44.1%	ON	Yes			
VALTREX (ORAL)	37.0%	ON	Yes			
FAMVIR (ORAL)	0.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Izard made the motion and Dr. Witkovsky seconded it.
 - All members were in favor of the motion.

ANTIVIRALS, TOPICAL						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ZOVIRAX OINTMENT (TOPICAL)	45.6%	NR	Yes			
DENAVIR (TOPICAL)	23.7%	NR	Yes			
ZOVIRAX CREAM (TOPICAL)	30.7%	NR	No			

- The Committee made a motion to accept the recommendations as presented.
 - Dr. Witkovsky made the motion and Dr. Boblin seconded it.
 - All members were in favor of the motion.

HEPATITIS B AGENTS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
EPIVIR HBV (ORAL)	41.7%	ON	Yes			
TYZEKA (ORAL)	1.0%	ON	Yes			
HEPSERA (ORAL)	27.1%	ON	Yes			
BARACLUDE (ORAL)	30.2%	ON	Yes			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Ms. Towers seconded it.
 - All members were in favor of the motion.

STEROIDS, TOPICAL LOW

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
HYDROCORTISONE (TOPICAL)	79.0%	NR	Yes-Generic			
DESONIDE (TOPICAL)	17.2%	NR	Yes-Generic			
DERMA-SMOOTHIE-FS (TOPICAL)	2.0%	NR	Yes			
ALCLOMETASONE DIPROPIONATE (TOPICAL)	1.4%	NR	No-Generic			
DESONATE (TOPICAL)	0.3%	NR	No			
VERDESO (TOPICAL)	0.2%	NR	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Brown made the motion and Dr. Fedderly seconded it.
 - All members were in favor of the motion.

STEROIDS, TOPICAL MEDIUM						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
LOCOID LIPOCREAM (TOPICAL)	1.1%	NR	Yes			
LUXIQ (TOPICAL)	1.3%	NR	Yes			
CORDRAN (TOPICAL)	0.1%	NR	No			
HYDROCORTISONE VALERATE (TOPICAL)	27.5%	NR	Yes-Generic			
FLUTICASONE PROPIONATE (TOPICAL)	21.9%	NR	Yes-Generic			
HYDROCORTISONE BUTYRATE (TOPICAL)	2.3%	NR	Yes-Generic			
MOMETASONE FUROATE (TOPICAL)	43.0%	NR	Yes-Generic			
PREDNICARBATE (TOPICAL)	0.7%	NR	No-Generic			
CLODERM (TOPICAL)	0.8%	NR	No			
CORDRAN TAPE (TOPICAL)	1.3%	NR	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Boblin made the motion and Ms. Barber seconded it.
 - All members were in favor of the motion.

STEROIDS, TOPICAL HIGH						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
CAPEX SHAMPOO (TOPICAL)	0.4%	NR	Yes			
TRIAMCINOLONE ACETONIDE (TOPICAL)	70.9%	NR	Yes-Generic			
BETAMETHASONE	3.2%	NR	Yes-Generic			

VALERATE (TOPICAL)						
FLUOCINOLONE ACETONIDE (TOPICAL)	2.8%	NR	Yes-Generic			
FLUOCINONIDE-E (TOPICAL)	0.2%	NR	Yes-Generic			
FLUOCINONIDE (TOPICAL)	6.5%	NR	Yes-Generic			
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.1%	NR	Yes-Generic			
DIFLORASONE DIACETATE (TOPICAL)	0.1%	NR	Yes-Generic			
BETAMETHASONE DIPROPIONATE (TOPICAL)	9.0%	NR	Yes-Generic			
HALOG (TOPICAL)	0.0%	NR	No			
AMCINONIDE (TOPICAL)	0.2%	NR	No-Generic			
DESOXIMETASONE (TOPICAL)	6.5%	NR	No-Generic			
VANOS (TOPICAL)	0.1%	NR	No			

- The Committee made a motion to approve the recommendation as presented.
 - Dr. Fedderly made the motion and Dr. Brown seconded it.
 - All members were in favor of the motion.

STEROIDS, TOPICAL VERY HIGH						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
CLOBETASOL PROPIONATE (TOPICAL)	80.4%	NR	Yes-Generic			
CLOBETASOL EMOLLIENT (TOPICAL)	4.2%	NR	Yes-Generic			
HALOBETASOL PROPIONATE (TOPICAL)	9.7%	NR	Yes-Generic			
CLOBEX (TOPICAL)	4.9%	NR	No			
OLUX-E (TOPICAL)	0.7%	NR	No			
OLUX-OLUX-E PACK (TOPICAL)	0.1%	NR	No			

- The Committee made a motion to approve the recommendations as presented.
 - Ms. Towers made the motion and Dr. Izard seconded it.
 - All members were in favor of the motion. .

ATOPIC DERMATITIS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ELIDEL (TOPICAL)	80.0%	OFF	No			
PROTOPIC (TOPICAL)	20.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Witkovsky made the motion and Dr. Boblin seconded it.
 - There were 10 members in favor of the motion and Rosanne Barber opposed the motion. Motion passed.

BRONCHODILATORS, ANTICHOLINERGIC						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
IPRATROPIUM NEBULIZER (INHALATION)	9.0%	ON	Yes-Generic			
COMBIVENT (INHALATION)	41.3%	ON	Yes			
ATROVENT HFA (INHALATION)	5.1%	ON	Yes			
SPIRIVA (INHALATION)	34.8%	ON	Yes			
IPRATROPIUM / ALBUTEROL NEBULIZER (INHALATION)	9.7%	ON	No-Generic			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Izard made the motion and Dr. Brown seconded it.
 - All members were in favor of the motion.

BRONCHODILATORS, BETA-AGONISTS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ALBUTEROL (ORAL)	1.3%	ON	Yes-Generic			
ALBUTEROL NEBULIZER (INHALATION)	19.7%	ON	Yes-Generic			
PROVENTIL HFA (INHALATION)	25.9%	ON	Yes			
XOPENEX HFA (INHALATION)	2.0%	ON	Yes			
VENTOLIN HFA (INHALATION)	5.6%	ON	Yes			
ALBUTEROL INHALER (INHALATION)	22.5%	ON	Yes-Generic			
PROAIR HFA INHALER (INHALATION)	18.1%	OFF	Yes			
ALUPENT INHALER (INHALATION)	0.0%	OFF	No			
METAPROTERENOL (ORAL)	0.0%	ON	Yes-Generic			
TERBUTALINE (ORAL)	0.2%	ON	Yes-Generic			
MAXAIR (INHALATION)	0.5%	ON	Yes			
FORADIL (INHALATION)	0.3%	OFF	Yes			

SEREVENT (INHALATION)	1.6%	ON	Yes			
ALBUTEROL NEBULIZER LOW-DOSE (INHALATION)	1.1%	ON	Yes-Generic			
XOPENEX (INHALATION)	1.1%	OFF	No			
METAPROTERENOL (INHALATION)	0.0%	OFF	No-Generic			
BROVANA (INHALATION)	0.0%	OFF	No			
PERFORMOMIST (INHALATION)	0.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Decker made the motion and Dr. Fedderly seconded it.
 - All members were in favor of the motion.

GLUCOCORTICOIDS, INHALED						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
QVAR (INHALATION)	2.6%	ON	Yes			
AZMACORT (INHALATION)	2.6%	ON	Yes			
AEROBID / AEROBID-M (INHALATION)	0.6%	ON	Yes			
FLOVENT / FLOVENT HFA (INHALATION)	20.2%	ON	Yes			
ASMANEX (INHALATION)	1.6%	ON	No			
PULMICORT FLEXHALER (INHALATION)	0.9%	OFF	No			
SYMBICORT (INHALATION)	0.8%	OFF	Yes			
ADVAIR / ADVAIR HFA (INHALATION)	59.4%	ON	Yes			
PULMICORT RESPULES (INHALATION)	11.4%	ON	Yes			

- The Committee made a motion to approve the recommendations as presented.
 - Ms. Towers made the motion and Mr. Maike seconded it.
 - All members were in favor of the motion.
 - Discussion: Dr. Izard was concerned that Asmanex was not a preferred agent and wondered why that was so.

INTRANASAL RHINITIS AGENTS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
FLUTICASONE	63.2%	ON	Yes-Generic			

(NASAL)						
ASTELIN (NASAL)	3.3%	ON	Yes			
BECONASE AQ (NASAL)	0.3%	OFF	No			
NASACORT AQ (NASAL)	12.3%	ON	Yes			
VERAMYST (NASAL)	0.9%	OFF	No			
IPRATROPIUM (NASAL)	2.8%	ON	Yes-Generic			
NASONEX (NASAL)	13.0%	OFF	No			
NASAREL (NASAL)	0.0%	OFF	No			
FLUNISOLIDE (NASAL)	1.3%	ON	Yes-Generic			
RHINOCORT AQUA (NASAL)	2.8%	OFF	No			
OMNARIS (NASAL)	0.0%	NR	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Dr. Brown seconded it.
 - All members were in favor of the motion.

LEUKOTRIENE MODIFIERS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ACCOLATE (ORAL)	1.8%	ON	Yes			
SINGULAIR (ORAL)	98.2%	ON	Yes			
ZYFLO CR (ORAL)	0.0%	NR	No			

- The Committee made a motion to approve the recommendation as presented.
 - Dr. Fedderly made the motion and Dr. Boblin seconded it.
 - All members were in favor of the motion. Dr. Iazard was not present for the vote.

PLATELET AGGREGATION INHIBITORS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
TICLOPIDINE (ORAL)	0.7%	ON	Yes-Generic			
DIPYRIDAMOLE (ORAL)	1.1%	ON	Yes-Generic			
PLAVIX (ORAL)	92.1%	ON	Yes			
AGGRENOX (ORAL)	6.1%	ON	Yes			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Boblin made the motion and Dr. Fedderly seconded it.
 - All members in favor of the motion. Dr. Iazard was not present for the vote.

OPHTHALMICS, NSAIDS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
FLURBIPROFEN (OPHTHALMIC)	0.7%	ON	Yes-Generic			
ACULAR LS (OPHTHALMIC)	72.1%	ON	Yes			
ACULAR PF (OPHTHALMIC)	0.1%	ON	Yes			
NEVANAC (OPHTHALMIC)	8.5%	ON	Yes			
XIBROM (OPHTHALMIC)	16.1%	ON	Yes			
DICLOFENAC (OPHTHALMIC)	2.5%	ON	No-Generic			

- The Committee made a motion to approve the recommendations as presented:
 - Dr. Izard made the motion and Dr. Witkovsky seconded it.
 - All members were in favor of the motion.

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ALREX (OPHTHALMIC)	3.4%	OFF	No			
KETOTIFEN OTC (OPHTHALMIC)	5.3%	ON	Yes-Generic			
CROMOLYN SODIUM (OPHTHALMIC)	12.6%	ON	Yes-Generic			
OPTIVAR (OPHTHALMIC)	9.2%	OFF	No			
ACULAR (OPHTHALMIC)	15.0%	OFF	No			
PATANOL (OPHTHALMIC)	45.4%	OFF	No		Yes	Yes
PATADAY (OPHTHALMIC)	6.7%	OFF	No		Yes	Yes
ELESTAT (OPHTHALMIC)	1.6%	OFF	No			
EMADINE (OPHTHALMIC)	0.1%	OFF	No			
ALOCRIIL (OPHTHALMIC)	0.1%	OFF	No			
ALOMIDE (OPHTHALMIC)	0.4%	OFF	No			
ALAMAST (OPHTHALMIC)	0.2%	OFF	No			
KETOTIFEN (OPHTHALMIC)	0.1%	OFF	No-Generic			

- Dr. Izard made a motion to consider adding Patanol and Pataday, and to have the Medicaid Director meet with the drug manufacturers to see if they would be willing to offer additional rebates. Dr. Fedderly seconded this motion.
 - All members were in favor of this motion.
- Dr. Fedderly made a second motion to approve the recommendations as presented and to accept Dr. Izard's first motion. Dr. Brown seconded this motion.
 - All members were in favor of the motion.

OPHTHALMICS, GLAUCOMA AGENTS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ISTALOL (OPHTHALMIC)	0.3%	ON	Yes			
LEVOBUNOLOL (OPHTHALMIC)	1.6%	ON	Yes-Generic			
DIPIVEFRIN (OPHTHALMIC)	0.1%	ON	Yes-Generic			
PILOCARPINE (OPHTHALMIC)	1.7%	ON	Yes-Generic			
AZOPT (OPHTHALMIC)	3.0%	ON	Yes			
TIMOLOL (OPHTHALMIC)	14.0%	ON	Yes-Generic			
BETIMOL (OPHTHALMIC)	1.8%	ON	Yes			
TRAVATAN / TRAVATAN Z 2.5 ML (OPHTHALMIC)	19.9%	ON	Yes			
CARTEOLOL (OPHTHALMIC)	0.4%	ON	Yes-Generic			
METIPRANOLOL (OPHTHALMIC)	0.1%	ON	Yes-Generic			
BETOPTIC S (OPHTHALMIC)	2.1%	ON	Yes			
BRIMONIDINE (OPHTHALMIC)	1.4%	ON	Yes-Generic			
LUMIGAN 2.5ML (OPHTHALMIC)	8.9%	ON	Yes			
COMBIGAN (OPHTHALMIC)	0.2%	NR	Yes			
XALATAN 2.5 ML (OPHTHALMIC)	14.5%	ON	No	Yes	No	No
BETAXOLOL (OPHTHALMIC)	0.1%	ON	Yes-Generic			
ALPHAGAN P (OPHTHALMIC)	10.4%	ON	Yes			
TRUSOPT (OPHTHALMIC)	1.7%	ON	Yes			
COSOPT (OPHTHALMIC)	8.5%	ON	Yes			

- Dr. Fedderly made a motion to accept the recommendations as presented and add Xalatan as a preferred agent. Ms. Barber seconded the motion.
 - Eight members were in favor of the motion and Shel Gross, Steve Maike and Mike Witkovsky were opposed to the motion. Motion passed.

OPHTH, QUINOLONES & MACROLIDES						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ERYTHROMYCIN (OPHTHALMIC)	34.7%	NR	Yes-Generic			
ZYMAR (OPHTHALMIC)	16.4%	ON	Yes			
VIGAMOX (OPHTHALMIC)	26.2%	ON	Yes			
OFLOXACIN (OPHTHALMIC)	4.2%	ON	Yes-Generic			
CIPROFLOXACIN SOLUTION (OPHTHALMIC)	17.6%	ON	Yes-Generic			
AZASITE (OPHTHALMIC)	0.3%	NR	No			
IQUIX (OPHTHALMIC)	0.1%	NR	Yes			

OPHTH, QUINOLONES & MACROLIDES

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
QUIXIN (OPHTHALMIC)	0.2%	OFF	No			
CILOXAN OINTMENT (OPHTHALMIC)	0.4%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Brown made the motion and Dr. Witkovsky seconded it.
 - All members were in favor of the motion.

ALZHEIMER'S AGENTS

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
ARICEPT / ARICEPT ODT (ORAL)	59.0%	ON	Yes			
EXELON (TRANSDERM.)	0.9%	OFF	No			
EXELON (ORAL)	3.4%	ON	No			
NAMENDA (ORAL)	30.8%	ON	Yes			
RAZADYNE / RAZADYNE ER (ORAL)	5.8%	OFF	No			
COGNEX (ORAL)	0.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Izard made the motion and Dr. Brown seconded it.
 - All members are in favor of the motion.
 - Members currently taking Exelon will be grandfathered on the drug indefinitely.

ANTIDEPRESSANTS, OTHER

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
TRAZODONE (ORAL)	25.9%	ON	Yes-Generic			
MIRTAZAPINE (ORAL)	14.6%	ON	Yes-Generic			
BUPROPION IR (ORAL)	1.6%	ON	Yes-Generic			
BUPROPION SR (ORAL)	15.0%	ON	Yes-Generic			
EFFEXOR XR (ORAL)	22.5%	ON	Yes			
NEFAZODONE (ORAL)	0.4%	OFF	No-Generic			
BUPROPION XL (ORAL)	8.1%	ON	Yes-Generic			
VENLAFAXINE (ORAL)	2.0%	ON	Yes-Generic			
PRISTIQ (ORAL)	0.0%	NR	No			
CYMBALTA (ORAL)	9.9%	OFF	No			
EMSAM (TRANSDERMAL)	0.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.

- Ms. Towers made the motion and Dr. Fedderly seconded it.
- All members were in favor of the motion.

ANTIDEPRESSANTS, SSRIs						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
CITALOPRAM	21.9%	ON	Yes-Generic			
FLUOXETINE	28.0%	ON	Yes-Generic			
SERTRALINE	26.2%	ON	Yes-Generic			
PAROXETINE	12.8%	ON	Yes-Generic			
FLUVOXAMINE	1.0%	ON	Yes-Generic			
PEXEVA (ORAL)	0.0%	OFF	No			
LEXAPRO (ORAL)	9.5%	OFF	No			
PAXIL CR (ORAL)	0.5%	OFF	No			
PROZAC WEEKLY	0.1%	OFF	No			
LUVOX CR (ORAL)	0.0%	NR	No			
PAROXETINE CR	0.0%	OFF	No-Generic			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Fedderly made the motion and Dr. Boblin seconded it.
 - All members were in favor of the motion.

ANTIPARKINSON'S AGENTS						
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
BENZTROPINE (ORAL)	30.6%	ON	Yes-Generic			
TRIHENYDYL (ORAL)	6.0%	ON	Yes-Generic			
SELEGILINE (ORAL)	0.7%	ON	Yes-Generic			
CARBIDOPA / LEVODOPA (ORAL)	25.9%	ON	Yes-Generic			
ROPINIROLE (ORAL)	21.9%	NA	Yes-Generic			
MIRAPEX (ORAL)	11.2%	OFF	No			
ZELAPAR (ORAL)	0.1%	OFF	No			
PARCOPA (ORAL)	0.1%	OFF	No			
BROMOCRIPTINE (ORAL)	1.1%	NR	Yes-Generic			
STALEVO (ORAL)	1.3%	ON	Yes			
COMTAN (ORAL)	0.7%	OFF	No			
NEUPRO (TRANSDERMAL)	0.3%	OFF	No			
AZILECT (ORAL)	0.1%	OFF	No			
TASMAR (ORAL)	0.1%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Ms. Towers made the motion and Dr. Fedderly seconded it.
 - All members were in favor of the motion.

ANTIPSYCHOTICS, ATYPICAL

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
CLOZAPINE (ORAL)	3.75%	ON	Yes-Generic			
FAZACLO (ORAL)	0.18%	OFF	No			
SEROQUEL (ORAL)	30.46%	ON	Yes			
GEODON (ORAL)	10.95%	ON	Yes			
RISPERDAL (ORAL)	28.52%	ON	Yes			
INVEGA (ORAL)	0.97%	OFF	No			
SYMBYAX (ORAL)	0.14%	OFF	No			
SEROQUEL XR	0.35%	OFF	No			
ABILIFY (ORAL)	14.72%	OFF	No		No	No
ZYPREXA (ORAL)	9.96%	OFF	No			

- Shel Gross made a motion to accept the recommendations as presented and add Abilify as a preferred agent. Dr. Izard seconded the motion.
 - Discussion: Dr. Witkovsky indicated that he supported the motion, but also wondered if the appropriate prescribers were prescribing atypicals and if the appropriate monitoring of patients taking these medications was occurring. He also voiced concerns about children taking these medications. Dr. Fedderly concurred with Dr. Witkovsky, especially with children taking these medications.
 - Three members were in favor of this motion including Shel Gross, Kevin Izard and Rosanne Barber. All others opposed the motion. Motion failed.
- Ms. Towers made a second motion that this be referred to the Mental Health Drug Advisors with the current recommendations. Dr. Fedderly seconded the motion.
 - All members were in favor of this motion.

STIMULANTS AND RELATED AGENTS

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Staff Recommendations	Secretary Modifications
AMPHETAMINE SALT COMBO (ORAL)	13.8%	ON	Yes-Generic			
METHYLPHENIDATE (ORAL)	10.3%	ON	Yes-Generic			
METHYLPHENIDATE ER (ORAL)	2.6%	ON	Yes-Generic			
VYVANSE (ORAL)	2.5%	OFF	Yes			
DEXMETHYLPHENIDATE (ORAL)	0.6%	ON	Yes-Generic			
DEXTROAMPHETAMINE (ORAL)	3.4%	ON	Yes-Generic			
METADATE CD (ORAL)	2.7%	ON	Yes			
ADDERALL XR (ORAL)	27.7%	ON	Yes			
DAYTRANA (TRANSDERMAL)	1.7%	OFF	No			
DESOXYN (ORAL)	0.0%	OFF	No			
FOCALIN XR (ORAL) (10FMANY)	4.7%	ON	Yes			

RITALIN LA (ORAL)	1.9%	OFF	No			
CONCERTA (ORAL) (NO RESTRICTIONS)	19.6%	ON	Yes			
STRATTERA (ORAL)	7.3%	OFF	No			
PROVIGIL (ORAL)	1.0%	OFF	No			

- The Committee made a motion to approve the recommendations as presented.
 - Dr. Witkovsky made the motion and Dr. Brown seconded it.
 - All members were in favor of the motion.

Dr. James Boblin made a motion to adjourn the meeting and Dr. Ward Brown seconded the motion. All members of the committee were in favor of this motion.